A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).

Trial Details

NCT ID

NCT05789082

Phase

PHASE1 / PHASE2

Sponsor

Hoffmann-La Roche

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Divarasib
Pembrolizumab
Carboplatin
Cisplatin
Pemetrexed

Locations (sample)

Duarte, California, United States|34.13945,-117.97729
Huntington Beach, California, United States|33.6603,-117.99923
Irvine, California, United States|33.66946,-117.82311
La Jolla, California, United States|32.84727,-117.2742
Long Beach, California, United States|33.76696,-118.18923

Key Eligibility Criteria

Confirmation of Biomarker eligibility
Pre-treatment tumor tissue along with an associated pathology report is required for all participants enrolled on study. Representative tumor speci…
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
Histologically or cytologically documented locally advanced unresectable or metastatic NSCLC that is not eligible for curative surgery and/or defin…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →